Please ensure Javascript is enabled for purposes of website accessibility
FDA Allows Emergency Use of Remdesivir for Coronavirus
gvw_ap_news
By Associated Press
Published 5 years ago on
May 1, 2020

Share

WASHINGTON — U.S. regulators on Friday allowed emergency use of an experimental drug that appears to help some coronavirus patients recover faster.

It is the first drug shown to help fight COVID-19, which has killed more than 230,000 people worldwide.

The FDA said in a statement that Gilead Science’s intravenous drug would be specifically indicated for hospitalized patients with “severe disease,” such as those experiencing breathing problems requiring supplemental oxygen or ventilators.

The study of 1,063 patients is the largest and most strict test of the drug and included a comparison group that received just usual care so remdesivir’s effects could be rigorously evaluated.

President Donald Trump announced the news at the White House alongside Gilead CEO Daniel O’Day and Food and Drug Administration Commissioner Stephen Hahn.

The FDA acted after preliminary results from a government-sponsored study showed that the drug, remdesivir, shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.

The study of 1,063 patients is the largest and most strict test of the drug and included a comparison group that received just usual care so remdesivir’s effects could be rigorously evaluated.

Those given the drug were able to leave the hospital in 11 days on average vs. 15 days for the comparison group.

The FDA said that performance warranted Friday’s decision, though regulators acknowledged “there is limited information known about the safety and effectiveness of using remdesivir.”

The drug’s side effects include potential inflammation of the liver and problems related to its infusion, which could lead to nausea, vomiting, sweating and low blood pressure. Fact sheets about dosing and potential safety issues will be provided to physicians and patients, the FDA said.

The National Institutes of Health’s Dr. Anthony Fauci said Wednesday the drug would become a new standard of care for severely ill COVID-19 patients. The drug, which blocks an enzyme the virus uses to copy its genetic material, has not been tested on people with milder illness.

The FDA authorized the drug under its emergency powers to quickly speed experimental drugs, tests and other medical products to patients during public health crises.

Remdesivir Will Still Need Formal Approval

In normal times the FDA requires “substantial evidence” of a drug’s safety and effectiveness, usually through one or more large, rigorously controlled patient studies. But during public health emergencies the agency can waive those standards, simply requiring that an experimental drug’s potential benefits outweigh its risks.

Gilead has said it would donate its currently available stock of the drug and is ramping up production to make more. It said the U.S. government would coordinate distribution of remdesivir to places most in need of it.

No drugs are approved now for treating the coronavirus, and remdesivir will still need formal approval.

The FDA can convert the drug’s status to full approval if Gilead or other researchers provide additional data of remdesivir’s safety and effectiveness.

“This is a very, very early stage so you wouldn’t expect to have any sort of full approval at this point,” said Cathy Burgess, an attorney specializing in FDA issues. “But obviously they want to get this out to patients as quickly as possible.”

The FDA previously allowed narrow use of a malaria drug, hydroxychloroquine, for hospitalized patients who were unable to take part in ongoing studies of the medication. Trump repeatedly promoted it as a possible COVID-19 treatment, but no large high-quality studies have shown the drug to work for that and it has significant safety concerns.

The FDA warned doctors late last month against prescribing the drug outside of hospital or research settings, due to risks of sometimes fatal heart side effects.

Two small studies published Friday add to concerns about the malaria drug. Critically ill COVID-19 patients given hydroxychloroquine were prone to heart rhythm problems, and for many risks mounted when it was combined with an antibiotic, the studies found.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

California Proposes Allowing Testing of Self-Driving Heavy-Duty Trucks

DON'T MISS

Higher Taxes on Millionaires? Trump Says He’s Open, but Many in His Party Are Not

DON'T MISS

Ex-US Rep. George Santos Sentenced to Over 7 Years in Prison for Fraud and Identity Theft

DON'T MISS

Selma Mayor Charged With Electioneering Violation on Election Day

DON'T MISS

Fresno Air Improves. Where Does It Rank in the US?

DON'T MISS

As Harris Ponders Run for CA Governor, Is She Prepared for the Daunting Job?

DON'T MISS

Stocks Rise With Tech-Related Shares, Notch Weekly Gains; Dollar Up

DON'T MISS

Conflicting US-China Talks Statements Add to Global Trade Confusion

DON'T MISS

Driving Near the Fresno Airport Next Week? Plan for Road Closures

DON'T MISS

Misty Her: Push for Fresno Unified Turnaround Starts Now With ‘Boots on the Ground’

UP NEXT

Exclusive: US Congress Republicans Seek $27 Billion for Golden Dome in Trump Tax Bill

UP NEXT

Fresno Unified Trustee Wittrup Says District Had Stronger Candidates Than Misty Her

UP NEXT

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

UP NEXT

Chicago Bears Great Steve McMichael Dies at 67 After Battle With ALS

UP NEXT

Long Wait Is Over for Cam Ward, Travis Hunter and Other Draft Prospects Joining the NFL

UP NEXT

Golden State’s Jimmy Butler Injured in Game 2 Loss, His Status for Game 3 Unknown

UP NEXT

Jalen Green Makes Eight 3s to Help Rockets Even Series With Warriors

UP NEXT

US Justice Department Directs Investigations Over Gender-Affirming Care

UP NEXT

Wired Wednesday: What’s the Future of Fresno Unified and the Superintendent Position?

UP NEXT

US Justice Department Cancels Hundreds of Grants for Police, Crime Victims

Selma Mayor Charged With Electioneering Violation on Election Day

2 hours ago

Fresno Air Improves. Where Does It Rank in the US?

3 hours ago

As Harris Ponders Run for CA Governor, Is She Prepared for the Daunting Job?

3 hours ago

Stocks Rise With Tech-Related Shares, Notch Weekly Gains; Dollar Up

4 hours ago

Conflicting US-China Talks Statements Add to Global Trade Confusion

4 hours ago

Driving Near the Fresno Airport Next Week? Plan for Road Closures

4 hours ago

Misty Her: Push for Fresno Unified Turnaround Starts Now With ‘Boots on the Ground’

4 hours ago

Fresno Police Arrest 17 in Domestic Violence Crackdown

4 hours ago

What’s Next for Fresno Smoke Shop Ordinance: Lawsuit, Veto, Override?

5 hours ago

Visalia Man Sentenced to Life in Prison for 2019 Fatal Stabbing

6 hours ago

California Proposes Allowing Testing of Self-Driving Heavy-Duty Trucks

LOS ANGELES — California regulators have released a new proposal to allow the testing of self-driving heavy duty trucks on public roads. The...

2 hours ago

2 hours ago

California Proposes Allowing Testing of Self-Driving Heavy-Duty Trucks

2 hours ago

Higher Taxes on Millionaires? Trump Says He’s Open, but Many in His Party Are Not

2 hours ago

Ex-US Rep. George Santos Sentenced to Over 7 Years in Prison for Fraud and Identity Theft

Selma Mayor Scott Robertson (left) has been charged with misdemeanor electioneering for allegedly campaigning near voters at a polling place during the November 2024 election. (Facebook)
2 hours ago

Selma Mayor Charged With Electioneering Violation on Election Day

3 hours ago

Fresno Air Improves. Where Does It Rank in the US?

3 hours ago

As Harris Ponders Run for CA Governor, Is She Prepared for the Daunting Job?

4 hours ago

Stocks Rise With Tech-Related Shares, Notch Weekly Gains; Dollar Up

A drone view shows containers at the terminals at the port in Kwai Chung in Hong Kong, China, April 3, 2025. (REUTERS/Tyrone Siu/File Photo)
4 hours ago

Conflicting US-China Talks Statements Add to Global Trade Confusion

Help continue the work that gets you the news that matters most.

Search

Send this to a friend